TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24130343

Group type: EXPERIMENTAL
Intervention: Booster-enhanced preconception counseling (READY-Girls) program
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care control group (CG)
Number of subjects: 109
Study: 21417809

Group type: EXPERIMENTAL
Intervention: Health Qigong (HQG) intervention group, n = 40
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group, n = 40
Number of subjects: 80
Study: 18490865

Group type: EXPERIMENTAL
Intervention: Carraguard vaginal gel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Methyl-cellulose placebo gel
Number of subjects: 55
Study: 17310818

Group type: EXPERIMENTAL
Intervention: Zidovudine-containing regimens
Number of subjects: 3314
Study: 12690904

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g orally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11006366

Group type: EXPERIMENTAL
Intervention: Irinotecan, fluorouracil, and leucovorin
Number of subjects: 683

Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 683
Study: 8780533

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1027
Study: 1514349

Group type: EXPERIMENTAL
Intervention: Flumazenil (6 micrograms.kg‐1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6735736

Group type: EXPERIMENTAL
Intervention: Intense intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple feedback of performance measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncoercive methods involving health care providers
Number of subjects: 0
Study: 30670043

Group type: EXPERIMENTAL
Intervention: Decision support tool and order set embedded in the EHR.
Number of subjects: 10939

Group type: COMPARATOR
Intervention: Control group with no alert for tobacco treatment.
Number of subjects: 10939
Study: 30577513

Group type: EXPERIMENTAL
Intervention: β‐Eudesmol beverage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 50
Study: 27614402

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dual tDCS
Number of subjects: 10
Study: 24835753

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Standard balance training
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 39
Study: 22973819

Group type: EXPERIMENTAL
Intervention: HIV-behavioural intervention
Number of subjects: 2070
Study: 20651593

Group type: EXPERIMENTAL
Intervention: External dacryocystorhinostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endonasal dacryocystorhinostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of external and endonasal dacryocystorhinostomy
Number of subjects: 0
Study: 18720937

Group type: EXPERIMENTAL
Intervention: Somatostatin 6 mg/day infused separately
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatostatin 6 mg/day added to TPN
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pre-treatment serum level
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-treatment serum level
Number of subjects: 10
Study: 15989121

Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive Interview (CI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Motivated, Repeated Recall (MRR)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Forced Interrogatory Recall Test (all conditions)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP) and Cognitive Interview (CI)
Number of subjects: 72
Study: 12447222

Group type: EXPERIMENTAL
Intervention: Prophy cup with fine flour pumice
Number of subjects: 22

Group type: COMPARATOR
Intervention: No. 23 dental explorer and air-water spray
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cotton pellet soaked in chlorhexidine gluconate, 0.12%
Number of subjects: 22
Study: 10955129

Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg as a first oral dose followed after 8 hrs by 150 mg (Group A)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg as a first dose, followed by the same dose 3 and again 8 hrs later (Group B)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg every 3 hrs, up to a total dose of 600 mg (Group C)
Number of subjects: 188
Study: 8551493

Group type: EXPERIMENTAL
Intervention: Celiprolol therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2182746

Group type: EXPERIMENTAL
Intervention: local hyperthermia combined with radiation
Number of subjects: 25

Group type: COMPARATOR
Intervention: radiation alone
Number of subjects: 25
Study: 23495

Group type: EXPERIMENTAL
Intervention: New-health-practitioner protocol system
Number of subjects: 472

Group type: COMPARATOR
Intervention: Physician-only nonprotocol system
Number of subjects: 472
Study: 31113453

Group type: EXPERIMENTAL
Intervention: Dynamic management support programme to increase innovation leadership skills
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no intervention initially)
Number of subjects: 8
Study: 29017497

Group type: EXPERIMENTAL
Intervention: Vildagliptin (DPP-4 inhibitor) add-on group
Number of subjects: 97

Group type: COMPARATOR
Intervention: High-dose metformin (double dose)
Number of subjects: 97
Study: 25624432

Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 1088
Study: 23812010

Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with Trabectome
Number of subjects: 55

Group type: COMPARATOR
Intervention: Phacoemulsification combined with trabecular aspiration
Number of subjects: 55
Study: 21910074

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis combined with hydroxychloroquine sulfate tablet (HCQ) for 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate tablet (HCQ) only for 3 months
Number of subjects: 68
Study: 18199279

Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride
Number of subjects: 0
Study: 16624227

Group type: EXPERIMENTAL
Intervention: Combined maintenance ECT plus nortriptyline
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 19
Study: 12879732

Group type: EXPERIMENTAL
Intervention: Standard physiotherapy plus manual lymph drainage
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard physiotherapy (control)
Number of subjects: 23
Study: 11079363

Group type: EXPERIMENTAL
Intervention: Trazodone 200 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 1618631

Group type: EXPERIMENTAL
Intervention: Health Belief Model‐Social Learning Theory (HBM‐SLT) program
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Comparison program
Number of subjects: 1444
Study: 6328288

Group type: EXPERIMENTAL
Intervention: Oral feeding with adequate vitamin D and phosphate supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral feeding with vitamin D supplementation
Number of subjects: 0
Study: 31018614

Group type: EXPERIMENTAL
Intervention: HIIT with beer (T-Beer group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HIIT with alcohol equivalent (T-Ethanol group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HIIT with alcohol-free beer (T-0.0Beer group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HIIT with sparkling water (T-Water group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-Training group
Number of subjects: 72
Study: 29771313

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25862567

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil and leucovorin
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel
Number of subjects: 346
Study: 24691218

Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy (12 weeks, twice per week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study: 22015737

Group type: EXPERIMENTAL
Intervention: Benzocaine 8 mg lozenge
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 165
Study: 20039221

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg . kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg . kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 75
Study: 17593871

Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy with preservation of both ovaries
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (menopausal patients with no previous ovarian pathology)
Number of subjects: 29
Study: 16037703

Group type: EXPERIMENTAL
Intervention: 4.5‐Fr catheter and 6‐Fr catheter (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4.5‐Fr catheter and 7‐Fr catheter (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure-flow studies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Detrusor pressure at maximum flow (Pdet. Qmax) and maximum detrusor pressure (P(det. max))
Number of subjects: 60
Study: 12100764

Group type: EXPERIMENTAL
Intervention: Salbutamol metered-dose inhaler (MDI) 1.2 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral administration of salbutamol 1.2 mg
Number of subjects: 10
Study: 10450579

Group type: EXPERIMENTAL
Intervention: Lateral thoracodorsal flap
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Latissimus dorsi flap
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Pedicled transverse rectus abdominis muscle flap
Number of subjects: 117

Group type: COMPARATOR
Intervention: Reference group (30 patients followed up outside the randomised study)
Number of subjects: 117
Study: 8767529

Group type: EXPERIMENTAL
Intervention: Melphalan/prednisone (MP) as first-line treatment in 84 patients (74%)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Patients with stage I-II disease
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Patients with stage III disease
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Responsive disease
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Refractory disease
Number of subjects: 113
Study: 1858732

Group type: EXPERIMENTAL
Intervention: Rice flour solution
Number of subjects: 66

Group type: COMPARATOR
Intervention: World Health Organization rehydration solution by gastric infusion
Number of subjects: 66

Group type: COMPARATOR
Intervention: World Health Organization rehydration solution orally
Number of subjects: 66
Study: 6621025

Group type: EXPERIMENTAL
Intervention: Thomsen-Friedenreich (T) antigen skin test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) blood levels
Number of subjects: 40
Study: 31514186

Group type: EXPERIMENTAL
Intervention: Increased antiphosphatidylserine antibodies (aPS) in patients with abnormal renal function
Number of subjects: 2874

Group type: EXPERIMENTAL
Intervention: Increased antiphosphatidylserine antibodies (aPS) in patients with normal renal function
Number of subjects: 2874

Group type: EXPERIMENTAL
Intervention: Comparison of aPS levels in patients with abnormal renal function
Number of subjects: 2874

Group type: EXPERIMENTAL
Intervention: Comparison of aPS levels in patients with normal renal function
Number of subjects: 2874
Study: 28297827

Group type: EXPERIMENTAL
Intervention: Bedside ultrasound monitoring of gastric residual volume every day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Syringes withdrawing every 8 hours to measure gastric residual volume
Number of subjects: 70
Study: 26806045

Group type: EXPERIMENTAL
Intervention: Plant sterols (3 g/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (low-fat spreads without added PS)
Number of subjects: 240
Study: 24886151

Group type: EXPERIMENTAL
Intervention: Supported cognitive behavioral therapy self-help (CBTsh) supported by mental health paraprofessionals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study: 22424003

Group type: EXPERIMENTAL
Intervention: Routine supplemental oxygen therapy
Number of subjects: 490

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 490
Study: 19802030

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study: 17931241

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant (10 cm x 10 cm)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control group (no gentamicin-collagen implant)
Number of subjects: 557
Study: 16219105

Group type: EXPERIMENTAL
Intervention: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine infusions weekly over 4 weeks.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks.
Number of subjects: 66
Study: 11914401

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 50
Study: 9872641

Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100% Oxygen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 70% Helium in 30% Oxygen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 70% Nitrous Oxide in 30% Oxygen
Number of subjects: 10
Study: 7613835

Group type: EXPERIMENTAL
Intervention: Anterior bladder neck tube reconstruction
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional posterior 'racket handle' closures
Number of subjects: 17
Study: 1958949

Group type: EXPERIMENTAL
Intervention: Agoraphobia
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Illness phobia
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Social phobia
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Fear of open spaces
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Frequency of panic attacks
Number of subjects: 1168
Study: 7318340

Group type: EXPERIMENTAL
Intervention: Saline infusion (2.25 mmol of Na+/kg) over 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic sodium loading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute sodium load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posture effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium effect on cell sodium transport
Number of subjects: 0
Study: 30884006

Group type: EXPERIMENTAL
Intervention: 90 seconds additional ablation duration
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 120 seconds additional ablation duration
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 150 seconds additional ablation duration
Number of subjects: 75
Study: 29096689

Group type: EXPERIMENTAL
Intervention: Rectally administered indomethacin
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1370
Study: 26551051

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 12 weeks
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 12 weeks
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 25 mg plus ribavirin for 8 weeks
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 8 weeks
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 100 mg plus ribavirin for 8 weeks
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 8 weeks
Number of subjects: 377
Study: 24169421

Group type: EXPERIMENTAL
Intervention: Informed consent documents (ICDs) with varying control over breadth of release of genetic information
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Informed consent documents (ICDs)
Number of subjects: 229
Study: 21537591

Group type: EXPERIMENTAL
Intervention: Sensi Kill
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxa-Gel
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 13
Study: 19281503

Group type: EXPERIMENTAL
Intervention: Immediate transmucosal tapered-effect (TE) implants placed in molar extraction sockets with buccal bone dehiscence
Number of subjects: 30

Group type: COMPARATOR
Intervention: Implants placed in healed molar sites (control sites)
Number of subjects: 30
Study: 17562636

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (specific methods not detailed)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study: 15105178

Group type: EXPERIMENTAL
Intervention: Residential exposure to magnetic fields
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Occupational exposure to magnetic fields (highest exposure)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Residential exposure to magnetic fields (ER-positive breast cancer)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Residential exposure to magnetic fields (ER-negative breast cancer)
Number of subjects: 44
Study: 11678784

Group type: EXPERIMENTAL
Intervention: Oxy-XL 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: IR-Oxy 5 mg
Number of subjects: 0
Study: 9832663

Group type: EXPERIMENTAL
Intervention: Warmed saline solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Room temperature saline solution
Number of subjects: 35
Study: 8076768

Group type: EXPERIMENTAL
Intervention: Interferon treatment (8.4-336 MU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interferon treatment (336 MU)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Other treatment protocols (lower dosages)
Number of subjects: 90
Study: 2642538

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy for 1 year
Number of subjects: 463

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 463

Group type: COMPARATOR
Intervention: Endocrine therapy alone for 1 year
Number of subjects: 463
Study: 322648

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Timolol 1.5% solution
Number of subjects: 30
Study: 31838199

Group type: EXPERIMENTAL
Intervention: SCD risk prediction model (based on age, sex, history of myocardial infarction, history of diabetes mellitus, presence of bundle branch block, N-terminal pro-brain natriuretic peptide level)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: High risk classification (predicted risk of SCD ≥10%)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: High SCD risk prediction
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: SCD risk model performance
Number of subjects: 615
Study: 31535715

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 759

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 759
Study: 28862758

Group type: EXPERIMENTAL
Intervention: Fremanezumab (225 mg or 675/225 mg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 25514103

Group type: EXPERIMENTAL
Intervention: Walk/run training for 10 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HDL3 isolated from MetS patients with walk/run training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (untrained state)
Number of subjects: 39
Study: 22908891

Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone during induction of anesthesia
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Short-course oral third-generation cephalosporin after ceftriaxone until nephrostomy catheter withdrawal
Number of subjects: 73
Study: 21660077

Group type: COMPARATOR
Intervention: Pioglitazone 45 mg/day for 12 months (n = 10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneously twice daily) for 12 months (n = 11)
Number of subjects: 21
Study: 19588536

Group type: EXPERIMENTAL
Intervention: 3 J cm(‐2) LED phototherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo phototherapy (<1.0 J cm(‐2))
Number of subjects: 28
Study: 17657403

Group type: EXPERIMENTAL
Intervention: Carotid artery stent placement (CAS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: S100beta protein evaluation
Number of subjects: 48
Study: 15541674

Group type: EXPERIMENTAL
Intervention: Charite artificial disc replacement
Number of subjects: 144

Group type: COMPARATOR
Intervention: BAK anterior interbody fusion
Number of subjects: 144
Study: 11566520

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of dexamethasone
Number of subjects: 104

Group type: COMPARATOR
Intervention: No subconjunctival steroid injection
Number of subjects: 104
Study: 9626918

Group type: COMPARATOR
Intervention: Formoterol 12 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formoterol 96 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All doses of formoterol
Number of subjects: 20
Study: 7956746

Group type: EXPERIMENTAL
Intervention: General practice interventions for alcohol misuse management
Number of subjects: 0
Study: 3585263

Group type: EXPERIMENTAL
Intervention: Triple antibiotic ointment (neomycin, polymyxin B, bacitracin) applied twice a day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Antiseptics
Number of subjects: 6

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Other antibiotic ointment
Number of subjects: 6
Study: 29526019

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy followed by systematic axillary-lymph-node dissection (sALND)
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Systematic axillary-lymph-node dissection (sALND) restricted to cases with positive SLN biopsy
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy followed by sALND
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (control arm)
Number of subjects: 1544
Study: 28255085

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham Control (SC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (IMT and SC)
Number of subjects: 25